Selecting Triple Negative Breast Cancer Patients for Immunotherapy

Stephanie Downs-Canner; Elizabeth A Mittendorf

doi:10.1016/j.soc.2023.05.005

Selecting Triple Negative Breast Cancer Patients for Immunotherapy

Surg Oncol Clin N Am. 2023 Oct;32(4):733-745. doi: 10.1016/j.soc.2023.05.005. Epub 2023 Jun 5.

Authors

Stephanie Downs-Canner¹, Elizabeth A Mittendorf²

Affiliations

¹ Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address: https://twitter.com/SDownsCanner.
² Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, Boston, MA, USA. Electronic address: emittendorf@bwh.harvard.edu.

PMID: 37714640
DOI: 10.1016/j.soc.2023.05.005

Abstract

The approval of preoperative immunotherapy combined with chemotherapy is a practice-changing advance for patients with early-stage triple-negative breast cancer. The optimal patient selection requires careful attention to staging and balancing potential risks with expected benefits, particularly as it relates to immune-related adverse events.

Keywords: Immunotherapy; Neoadjuvant; Pembrolizumab; Triple negative breast cancer.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Humans
Immunotherapy
Patient Selection
Triple Negative Breast Neoplasms* / drug therapy

Grants and funding

K08 CA259533/CA/NCI NIH HHS/United States